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Abstract
Background: Combination therapy using acetylcholinesterase inhibitors (AChEIs) and cilostazol is of unknown
efficacy for patients with Alzheimer’s disease (AD).
Methods: We explored the therapeutic responses by using a case–control study, which was conducted in Taiwan.
We enrolled 30 participants with stable AD who were receiving cilostazol (50 mg) twice per day as an add-on
therapy combined with AChEIs, and 30 participants as controls who were not receiving cilostazol as an add-on
therapy. The therapeutic responses were measured using neuropsychological assessments and analyzed in relation
to cilostazol use, apolipoprotein E genotype, and demographic characteristics. Mini-mental state examination
(MMSE) and clinical dementia rating sum of boxes (CDR-SB) were administered at the outset of the study and 12
months later. Multiple logistic regression analysis was used to estimate the association between the therapeutic
response and cilostazol use.
Results: For the therapeutic indicator of cognition, Cilostazol use (adjusted odds ratio (aOR) = 0.17, 95% confidence
interval (CI) = 0.03–0.80), initial CDR-SB score (aOR = 2.06, 95% CI = 1.31–3.72), and initial MMSE score (aOR = 1.41,
95% CI = 1.11–1.90), but not age, sex, education, or ApoE ε4 status, were significantly associated with poor therapeutic
outcomes. For the therapeutic indicator of global status, no significant association was observed between the
covariates and poor therapeutic outcomes.
Conclusions: Cilostazol may reduce the decline of cognitive function in stable AD patients when applied as an
add-on therapy.
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Background
More than 35 million people worldwide [1] and 5.5 million
people in the United States have Alzheimer’s disease (AD).
AD causes deterioration of the memory and other cogni-
tive domains, thereby increasing morbidity and mortality
in the elderly population [2].
AD is the most common form of dementia, accounting
for 50–56% of cases at autopsy and in clinical series. In
addition, AD combined with intracerebral vascular disease
accounts for another 13–17% of cases. The principal risk
factor for AD is advanced age. The incidence of AD
doubles every 5 years after 65 years of age, with 1275
new cases diagnosed per year per 100, 000 people aged
65 years or more [3, 4]. Moreover, AD is one of the most
common causes of disability in the elderly population [2],
thereby having a considerable effect on caregivers. In
2010, dementia resulted in approximately 486,000 deaths
[5]. In developed countries, AD has one of the highest
economic burdens of all diseases [6].
No cure currently exists for AD [7, 8]. Acetylcholin-
esterase inhibitors (AChEIs) are often used and may be
beneficial in mild-to-moderate cases. However, their over-
all benefit may be minor [9]. New treatment modalities
for AD such as immunotherapy, γ-secretase inhibitors,
and cerebral circulation attenuation are promising [10].
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Cilostazol is a selective inhibitor of cyclic nucleotide
phosphodiesterase 3 (PDE3). Cilostazol possesses many
pharmacological activities including anti-inflammatory,
antioxidative, and antiapoptotic effects in the brain [11].
In addition, cilostazol prevented cerebral hypoperfusion-
induced cognitive impairment and white matter damage
in a rat model by the occlusion of the common carotid
artery through bilateral ligation [12]. A more recent pre-
liminary study involving 10 patients with moderate AD
demonstrated that a combination therapy of donepezil
and cilostazol significantly improved Mini-Mental State
Exam (MMSE) scores and maintained the status of par-
ticipants unchanged until the end of the follow-up
period [13]. Cilostazol may prevent the neuronal death
and cognitive impairment caused by AD. However, the
sample size in the study was small (10 patients) and the
follow-up period was relatively short (an average of 6–7
months). In addition, the efficacy of only the combin-
ation therapy of donepezil and cilostazol was evaluated.
In the current study, we examined the therapeutic re-
sponse to cilostazol as an add-on therapy in patients
with stable AD receiving AChEIs in Taiwan. We hypoth-
esized that cilostazol, which is a phosphodiesterase 3 in-




To investigate the effect of cilostazol as an add-on ther-
apy in patients with stable AD receiving AChEIs, we
conducted a case–control study in the regional teaching
hospital of Kaohsiung Municipal Ta-Tung Hospital in
southern Taiwan.
We included 30 patients with stable AD receiving
cilostazol (50 mg) twice per day as an add-on therapy
with AChEIs for at least 12 months between December
2014 and December 2015 in the study group. The pa-
tients with stable AD were defined as those with satisfac-
tory medication adherence, 30 days or fewer without
AChEIs in the past year, and follow-up visit compliance
of at least 80%. No adjustment of the dosage of AChEIs
or use of any other add-on anti-dementia medication
was allowed during the study period. We matched each
study patient with one patient with stable AD receiving
AChEIs for at least 12 months, applying their age
(within 2 years) and educational level as a control. The
patients in the control group did not receive cilostazol
(50 mg) as an add-on therapy.
The AD diagnosis was based on the National Institute
of Neurological and Communicative Disorders and Stroke
and the Alzheimer's Disease and Related Disorders Asso-
ciation criteria [14], which include a series of comprehen-
sive neuropsychological tests such as the MMSE [15],
Cognitive Assessment Screening Instrument (CASI) [16],
Neuropsychiatric Inventory [17], and Clinical Dementia
Rating Sum of Boxes (CDR-SB) [18]. Patients with other
conditions possibly contributing to their AD diagnosis
were excluded (including nutritional deficiency, metabolic
encephalopathy, hypothyroidism, toxin, and CNS infection
or tumor).
Evaluation
Various neuropsychological assessments including the
MMSE, CASI, and CDR-SB were performed initially and
every 6 months thereafter with all patients to evaluate
their therapeutic response to the AChEIs. These assess-
ments were performed by a senior neuropsychologist and
an experienced physician based on information provided
by a knowledgeable collateral source (usually a spouse or
adult child). All primary outcomes were measured at the
12th month of the follow-up period after joining the study.
Intra-individual comparison of therapeutic responses
was conducted using two indicators: cognitive function
(assessed using the MMSE) and global status (assessed
using the CDR-SB). The patients with a second MMSE
score equal to or higher than their first MMSE score
(MMSE score ≥ 0) were considered as having a favorable
response, whereas those with a lower second score were
considered as having a poor response. Similarly, the pa-
tients with a second CDR-SB score lower than or equal to
their first CDR-SB score (CDR-SB score ≤ 0) were con-
sidered as having a favorable response, whereas those
with a higher score were considered as having a poor
response. This study was approved by the Institutional
Review Board of Kaohsiung Medical University Hospital
(KMUHIRB-20140063), and written informed consent was
obtained from all the patients or their legal representatives.
ApoE genotyping
In all patients, the restriction enzyme iso-typing of the
ApoE allele was performed following a modification of
the protocol developed by PyrosequencerTM (http://
www.pyrosequencing.com). Briefly, 10 ng of DNA was
amplified in a 20-L reaction volume in which dGTP was
replaced by a mixture of 25% dGTP and 75% dITP to fa-
cilitate analysis of the GC-rich fragment. A 276-bp frag-
ment was generated using the forward primer AGA
CGC GGG CAC GGC TGT and the reverse biotin-
labeled primer CTC GCGGAT GGC GCT GAG. The
single-stranded DNA prepared using streptavidin-coated
beads and ApoE variants at codons 112 and 158 were
pyrosequenced using the primers SNP112 GAC ATG
GAG GAC GTG and SNP158CCG ATG ACC TGC
AGA, applying the dispensation order GCTGAGC-
TAGCGT. Patients with one or two copies of the ApoE
ε4 allele were considered ApoE ε4-positive, and those
with no copy of the ApoE ε4 allele were considered
ApoE ε4-negative.
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Statistical analysis
Data analysis was performed using the Statistical Package
for Social Sciences software (Standard Version 11.5.0;
SPSS Inc., Chicago, IL, USA). All statistical tests were
2-tailed, and an alpha value of .05 indicated significance.
The t test was used to assess differences between the two
independent groups (i.e., the favorable and poor response
groups) regarding age, educational level, initial CDR-SB
score, initial MMSE score, second CDR-SB score, and
second MMSE score. The chi-squared test was used to
compare the case–control and therapeutic groups with
regard to the ApoE ε4 genotype and sex. In addition, the
chi-squared test was used to compare the therapeutic
groups with regard to cilostazol use.
Multiple logistic regression models were fit to the data
to calculate the odds ratios (ORs) and 95% confidence
intervals (CIs) of the association between the therapeutic
response and cilostazol use. This model was adjusted for
age, sex, educational level, initial MMSE score, initial
CDR-SB score, and ApoE ε4 status.
The dependent variable in each logistic regression
model was the response (favorable or poor), and either
of the therapeutic indicators was examined separately.
Independent variables, including age, educational level,
initial CDR-SB score, and initial MMSE score, were
treated as continuous variables with 1-year increments
for age and educational level and 1-score increments for
CDR-SB and MMSE scores. This contrasted with the di-
chotomous categorical variables including cilostazol use,
sex, and ApoE ε4 status. The R squared for the logistic
regressions is 31.12%. The lack of fit chi-squared is not
significant (Prob > ChiSq = 0.2791).
Results
The age, sex, educational level, first and second MMSE
and CDR-SB scores, and ApoE genotyping results of all the
particpants are presented in Table 1. Their average age,
educational level, initial MMSE score, initial CDR-SB score,
12th-month MMSE score, and 12th-month CDR-SB score
were 82.4 years, 7.8 years, 14.5, 8.1, 12.0, and 9.4, respect-
ively, with no significant differences between the study and
control groups. Of the patients, a majority were women
(76.7%) and ApoE ε4-negative (78.2%), with no significant
differences between the study and control groups.
Table 2 shows factors associated with the therapeutic
indicator of cognition. For the MMSE score, 31.7% of all
participants had a favorable response, whereas 68.3%
had a poor response. Moreover, significant differences
were observed between the 2 therapeutic groups in cilos-
tazol use (P = .015) but not in initial MMSE score, initial
CDR-SB score, age, sex, educational level, or ApoE ε4
status (Table 2). However, after adjustment for other
covariates in the logistic regression analysis, cilostazol
use (OR = 0.17, 95% CI = 0.03–0.80, P = .024), initial
CDR-SB score (OR = 2.06, 95% CI = 1.31–3.72, P < .001),
and initial MMSE score (OR = 1.41, 95% CI = 1.11–1.90,
P = .004), but not age, sex, education, or ApoE ε4 status,
were significantly associated with poor therapeutic out-
comes (Table 3).
Table 4 shows factors associated with the therapeutic
indicator of global status. For CDR_SB, 37.9% of all par-
ticipants exhibited a favorable response, whereas 62.1%
exhibited a poor response. No significant differences
were observed between the 2 therapeutic groups in age,
sex, educational level, initial MMSE score, or ApoE ε4
status (Table 4). In the logistic regression analysis, no
significant association was observed between covariates
and poor therapeutic outcomes (Table 5).
Discussion
The main finding of this study is that cilostazol add-on
therapy was associated with reduced odds of clinical de-
terioration of cognitive function for approximately 1 year
in patients with stable AD who had received AChEIs for
Table 1 Baseline characteristics of case and control groups
Case (N = 30) Control (N = 30) p-value
Age, years (mean ± SD) 82.8 ± 5.2 82.0 ± 5.9 0.580
Education, years (mean ± SD) 8.1 ± 4.3 7.6 ± 5.2 0.722
Gender, female (%) 21 (70.0) 25 (83.3) 0.222
1st MMSE 14.0 ± 6.5 14.9 ± 6.1 0.585
1st CDR_SB 8.8 ± 3.5 7.3 ± 3.1 0.103
2nd MMSE 11.5 ± 8.1 12.5 ± 7.3 0.617
2nd CDR_SB 9.9 ± 4.0 8.9 ± 3.4 0.290
ApoE ε4(+),n (%) 5 (16.7) 7 (23.3) 0.469
Case: participants using cilostazol for one year; Control: participants matching
case participants 1:1 for age and education but not using cilostazol for one year
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum
of Boxes scale, ApoE apolipoprotein E
Table 2 Therapeutic indicator of cognition: ΔMMSE
Therapeutic response,
N (%)
Favorablea,21 (31.7) Poorb,39(68.3) p-value
Age, years (mean ± SD) 82.3 ± 5.6 82.5 ± 5.6 0.908
Education, years
(mean ± SD)
7.5 ± 4.7 8.1 ± 4.8 0.634
Gender, female (%) 15 (71.4) 31 (79.5) 0.482
1st CDR-SB 7.4 ± 3.6 8.4 ± 3.3 0.292
1st MMSE 14.1 ± 7.1 14.6 ± 5.9 0.766
Cilostazol use 0.015
No 6 (20.0) 24 (80.0)
Yes 15 (50.0) 15 (50.0)
ApoE ε4(+),n (%) 7 (35.0) 5 (14.3) 0.074
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum
of Boxes scale, ApoE apolipoprotein E, ΔMMSE 2nd MMSE – 1st MMSE
aΔMMSE ≥0
bΔMMSE < 0
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at least 12 months. In addition, we observed that high
initial MMSE and CDR-SB scores were significantly as-
sociated with poor therapeutic responses in cognition.
By contrast, cilostazol use, initial MMSE score, and ini-
tial CDR-SB score were not significantly associated with
poor therapeutic responses in global status. Moreover,
ApoE ε4 status and sex were not associated with thera-
peutic outcomes in cognition and functional status.
Cilostazol, an antiplatelet drug, improved cerebral cir-
culation, reduced amyloid beta (Aβ) accumulation, and
improved brain functioning in an experimental AD
model [19]. A retrospective study reported that cilosta-
zol improved cognitive function in patients with mild
cognitive impairment [20]. Moreover, a pilot study of 10
patients with moderate AD conducted in a clinical set-
ting reported that cilostazol reduced the rate of cognitive
decline when co-administered with donepezil after an
average follow-up period of 9.4 months [13]. In addition,
cilostazol effectively suppressed cognitive decline in pa-
tients with AD and comorbid cerebro-vascular diseases
[21] and in patients with mild dementia receiving done-
pezil, but did not have this effect in those with moderate
and severe dementia [22]. In the current study, cerebral
circulatory impairment and Aβ accumulation may have
coexisted and varied significantly between patients. How-
ever, this situation may be representative of that generally
observed in the elderly population, indicating the clinical
relevance of administering a drug that has dual roles in is-
chemia and Aβ-induced neuro-degeneration. Thus, the
preservation of cognitive function in patients with AD re-
ceiving a combination therapy of cilostazol and AChEIs
may be clinically significant. One of the plausible mechan-
istic explanations for the positive effect of this combinator-
ial therapy is that AChEIs and cilostazol have different
vascular targets. AChEIs increase acetylcholine levels,
which in turn dilates vessels in an endothelium-dependent
manner, whereas cilostazol targets PDE3 in the vascular
smooth muscle cells and thus causes vasodilation in an
endothelium-independent manner. Several “single-target,
single-action” treatments for AD, such as antiamyloid
agents, antioxidants, and anti-inflammatory drugs, have
mostly failed or performed poorly in large clinical trials
[23], leading to the complementary “neurovascular hy-
pothesis.” [24] In AD, multiple pathogenic cascades ori-
ginating from the altered vasculature can initiate the
disintegration of the neurovascular unit, which can
amplify Aβ deposition, as well as synaptic, neuronal,
and glial dysfunction, and subsequent cognitive decline
[25]. The current study suggests that vasoactive cilosta-
zol may be a promising new therapeutic approach to
maximizing the potential to improve cognitive function
in patients with AD receiving AChEIs.
During the evaluation of therapeutic responses in global
status, we observed that cilostazol use, initial global status,
and initial cognitive function were not significantly associ-
ated with the worsening of global status, despite our pa-
tients already receiving AChEIs. These results differ from
those of previous studies, which have reported that clinical
Table 3 Logistic regression for the therapeutic indicator of
cognition: ΔMMSE
odds ratio 95% CI p-value
Age, years (mean ± SD) 0.96 0.82–1.13 0.645
Education, years (mean ± SD) 0.95 0.79–1.15 0.584
Gender, female (%) 2.23 0.34–16.02 0.401
1st CDR–SB 2.06 1.31–3.72 <0.001
1st MMSE 1.41 1.11–1.90 0.004
Cilostazol use 0.17 0.03–0.80 0.024
ApoE ε4(+), n (%) 0.30 0.04–1.90 0.3173
Odds ratios are based on comparing odds of poor (ΔMMSE < 0) versus
favorable (ΔMMSE ≥0) therapeutic indicators of cognition
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum
of Boxes scale; ApoE apolipoprotein E, ΔMMSE: 2nd MMSE–1st MMSE
Table 4 Therapeutic indicator of global status: ΔCDR-SB
Therapeutic response,
N (%)
Favorablea,22 (37.9) Poorb,36 (62.1) p-value
Age, years (mean ± SD) 82.1 ± 6.2 82.7 ± 5.3 0.741
Education, years
(mean ± SD)
7.7 ± 5.1 7.9 ± 4.6 0.888
Gender, female (%) 14 (63.6) 30 (83.3) 0.089
1st CDR-SB 8.8 ± 3.6 7.6 ± 3.2 0.207
1st MMSE 13.8 ± 6.7 14.9 ± 6.1 0.534
Cilostazol use 0.104
Yes 14 (48.3) 15 (51.7)
No 8 (27.6) 21 (72.4)
ApoE ε4(+),n (%) 6 (31.6) 6 (17.7) 0.245
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum
of Boxes scale; ApoE apolipoprotein E, ΔCDR_SB: 2nd CDR_SB – 1st CDR_SB
aΔCDR_SB ≤ 0
bCDR_SB > 0
Table 5 Logistic regression for the therapeutic indicator of
global status: ΔCDR-SB
odds ratio 95% CI p-value
Age, years (mean ± SD) 1.01 0.88–1.15 0.920
Education, years (mean ± SD) 1.02 0.88–1.21 0.778
Gender, female (%) 3.33 0.68–18.62 0.146
1st CDR-SB 0.90 0.63–1.28 0.573
1st MMSE 1.00 0.82–1.22 0.962
Cilostazol use 0.51 0.12–1.99 0.331
ApoE ε4(+),n (%) 0.39 0.07–1.92 0.248
Odds ratios are based on comparing odds of poor (CDR_SB > 0) versus
favorable (ΔCDR_SB ≤ 0) therapeutic indicators of global status
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum
of Boxes scale, ApoE apolipoprotein E, ΔCDR_SB: 2nd CDR_SB–1st CDR_SB
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deterioration is more common in the more advanced
stages of dementia than in the early stages of dementia
[26, 27]; moreover, patients in these studies were already
receiving donepezil. Such findings may be partly due to
different patients’ age and therapy strategies.
Our study has several strengths. First, unlike other
studies, we evaluated the effect of the combination ther-
apy of cilostazol and any AChEI, rather than only done-
pezil. Second, we controlled other variables, including
age, sex, educational level, and ApoE ε4 status to have
fewer confounding factors. Third, a previously published
clinical trial obtained significant results by comparing
the therapeutic effects of combination therapy (donepe-
zil and cilostazol) with those of only donepezil therapy
and by comparing mean differences in neurological mea-
surements among groups. However, these results cannot
be easily duplicated and applied in every patient with
AD because not all patients respond to such treatments.
We performed intra-individual comparisons to evaluate
the therapeutic responses of patients with AD because,
in real clinical settings, therapeutic responses are evalu-
ated by comparing the current conditions of patients
with their previous conditions.
Our study had some limitations that should be addressed.
First, we used MMSE and CDR-SB, but not other neuro-
logical measurements, as therapeutic indicators, and these
measurements may be insufficient for measuring the overall
therapeutic response of patients with AD. Notably, previous
studies have used changes from baseline MMSE [28] and
CDR-SB [29] scores as therapeutic indicators. No consen-
sus has been reached on the most efficient therapeutic pa-
rameters for reflecting the clinical condition of patients
with AD receiving AChEIs. Second, we did not have de-
tailed information on the type of AChEI used by each pa-
tient. Thus, we could not distinguish the effects of different
AChEIs. However, the overall benefit of AChEIs remains
limited [8].
Third, we did not consider the effects of concomitant
medications, comorbid medical illnesses, or stroke.
However, we conducted physical and neurological ex-
aminations in all the patients to detect any possible
confounding factors. Moreover, according to Taiwan
National Health Insurance rules and our study design, a
minimum requirement is that patients with AD receiv-
ing AChEIs should undergo brain computed tomog-
raphy to ensure no evidence of stroke as well as
laboratory testing to rule out the presence other med-
ical illnesses contributing to the AD diagnosis. Add-
itional studies can be conducted to clarify the effect of
these confounding factors. Finally, the proportion of
apolipoprotein E (APOE) ε4 carriers in this study is
relatively lower than that in other populations despite
the similar proportion in previous studies in Taiwan.
This may limit the possibility of external generalization.
Conclusion
Our results indicate that cilostazol, which affects both
cerebral circulation and Aβ metabolism, may reduce the
odds of clinical deterioration of cognitive function in pa-
tients with stable AD. Because no fundamental treatment
is available for AD, new therapies should be developed.
Our results highlight the need for a comprehensive pro-
spective cohort study to clarify the therapeutic response of
cilostazol on the preservation of cognitive function in pa-
tients with AD.
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